Disease-free (DFS) and overall survival (OS) at 3.4 years (yrs) for neoadjuvant bevacizumab (Bev) added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC), for women with HER2 negative early breast cancer: The ARTemis trial.
Authors: Earl, H.M., Hiller, L., Dunn, J., Blenkinsop, C., Grybowicz, L., Vallier, A.-L., Abraham, J., Hughes-Davies, L., McAdam, K., Chan, S., Ahmad, R., Hickish, T., Houston, S., Rea, D., Bartlett, J., Caldas, C., Cameron, D.A., Provenzano, E., Thomas, J., Hayward, L.
Journal: JOURNAL OF CLINICAL ONCOLOGY
Publication Date: 20/05/2016
Volume: 34
Issue: 15
eISSN: 1527-7755
ISSN: 0732-183X
DOI: 10.1200/JCO.2016.34.15_suppl.1014
Source: Web of Science